King Faisal Specialist Hospital & research Center
Riyadh, 11211, Saudi Arabia
NCT Number: NCT01501591
The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug, the investigators have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
Riyadh, 11211, Saudi Arabia
BACKGROUND:
The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their possible interaction. Current interpretation of the results of clinical trials (the gold standard in evidence based medicine) assumes no such interaction. Using a novel cross-over balanced placebo design and caffeine as a model drug we have recently shown that a negative interaction does exist; suggesting that the size of drug effect as currently measured by clinical trials may not be accurate. Due to the novelty of the findings and their important clinical practice and research implications, they need to be confirmed using another drug; and the size of drug effect measured using the novel design need to be directly compared to that measured using conventional clinical trial design.
DESIGN:
A cross-over balanced placebo plus randomized placebo-controlled clinical trial design.
METHODS:
480 adults will be double-blindly randomized to three groups: first generation H-1 receptor antagonist- hydroxyzine (25 mg), placebo, or hydroxyzine+placebo group. The first two groups will receive the assigned intervention described by the investigators as hydroxyzine or placebo, in a randomized crossover design. The third group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design. Group assignment will be concealed from volunteers and recruiters. Data collectors will be blinded to group assignment and intervention assignment. Volunteers will be partially deceived to the intervention assignment in the first two groups and blinded in the third group. The interventions to the third group will be also administered blindly. Serum hydroxyzine levels will be determined 3 hours post intervention from all volunteers to verify compliance and help maintain deception/blinding. The results of the study are expected to further our understanding of a widely used medical intervention, i.e., placebo, and help assess the appropriateness of randomized clinical trials in determining the size of drug effect.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25 mg orally, one time on two different days, 72 hours apart
Matching placebo once on two different days, 72 hours apart.
25 mg hydroxyzine or placebo once on two different days, 72 hours apart
Time frame: seven hours
Seven-hour-area-under-the-curve of drowsiness on 100 mm visual analog scales will be determined
Time frame: seven hours
Seven-hour-area-under-the-curve of dryness of the mouth on 100 mm visual analog scales will be determined
Time frame: seven hours
Mean percent of time of reporting drowsiness on a dichotomous scale will also be determined.
Time frame: seven hours
Mean percent of time of reporting dryness of mouth on a dichotomous scale will also be determined.
King Faisal Specialist Hospital & Research Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06423365
Cardiovascular Diseases, Dyslipidemias
Aurora, Colorado, United States
View Trial DetailsNCT02802241
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT04571827
Disability, Dry Needling
Madrid, Spain
View Trial DetailsNCT05004467
Disability Physical, Neck Pain
Madrid, Spain
View Trial Details